Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03287518
Other study ID # WOA/002017
Secondary ID
Status Recruiting
Phase N/A
First received September 8, 2017
Last updated November 8, 2017
Start date July 28, 2017
Est. completion date September 15, 2018

Study information

Verified date October 2017
Source Analyze & Realize
Contact Maya Ulbricht
Phone 0049 3040 00 8
Email mulbricht@a-r.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of the study is to evaluate the endothelial function of WAK2017. In addition the effects on the blood pressure and the parameters of lipid metabolism will be explored.


Description:

The main objective of the study is to evaluate the endothelial function of WAK2017. In addition the effects on the blood pressure and the parameters of lipid metabolism will be explored.

Primary endpoint is defined as the difference in change in EndoPAT score RHI pre-dose and after 12 weeks of IP intake (visit V4 vs. V2) in comparison between the verum and placebo.

To characterize the benefit of the IP the following secondary endpoints will be analysed in comparison be-tween the verum and placebo:

- EndoPAT AI at V4 vs. V2

- SBP at V3, V4 vs. V2, respectively

- DBP at V3, V4 vs. V2, respectively

- Fasting LDL-C concentrations and non-HDL-C at V3, V4 vs. V2, respectively

- Fasting TC concentrations at V3, V4 vs. V2, respec-tively

- Fasting HDL-C concentrations at V3, V4 vs. V2, respectively

- Fasting TG concentrations at V3, V4 vs. V2, respectively

- Fasting LDL-C/HDL-C and TC/HDL-C ratio at V3, V4 vs. V2, respectively

- SCORE value at V3, V4 vs. V2, respectively

- Global evaluation of benefit by the subjects/ investigator at V4


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 15, 2018
Est. primary completion date April 1, 2018
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

1. Male and female subjects, 40-75 years

2. BMI 25-34.9 kg/m2

3. High normal or hypertension grade 1 blood pressure levels (130-159 / 85-99 mmHg) both at screening (mean of the 2nd and 3rd measurement during the assessment in triplicate at V1) and at baseline (mean of the 2nd and 3rd measurement during the assessment in triplicate at V2)

4. EndoPAT score (RHI): < 2.2 at V1

5. Readiness to comply with study procedures, in particular:

- Consumption of the IP as instructed during the treatment period

- Adhering to former diet (except consumption of max. 2 garlic cloves per week) and physical activity

- Requirements for blood pressure / EndoPAT measurements

- Accepting blood draws

6. Non-smoker / smoking cessation of last =12 months prior to V1

7. Stable body weight in the last 3 months prior to V1 (<3 kg self-reported change)

8. If allowed concomitant medications are taken this must have been stable at least during the last month prior to V1

9. Women of childbearing potential:

- Negative pregnancy testing (beta HCG-test in urine) at V1

- Commitment to use reliable contraception methods during the study Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.

Exclusion Criteria:

1. Known allergy or hypersensitivity to the components of the investigational product

2. Known genetic hyperlipidemia

3. Known secondary hypertension

4. Known white-coat hypertension

5. Known type-1-diabetes

6. Uncontrolled or within the last 6 months prior to V1 diagnosed type-2-diabetes

7. Untreated or non-stabilized thyroid disorder

8. History and/or presence of clinically significant cardiovascular disease as per investigator's judgement:

- Known congenital heart defects

- Myocardial infarction, heart failure, angina pectoris, life-threatening arrhythmia or stroke within the last 6 months prior to V1

- Existing thrombosis or disposition to thrombosis

9. Any other known significant or serious condition / disease that renders subjects ineligible, e.g.:

- History of malignancy within the past 5 years prior to V1

- Bleeding disorder and/or need for anticoagulants

- Current psychiatric care and/or use of neuroleptics

- Bariatric surgery in the last 12 months prior to V1

10. Any known metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subject

11. Known arm lymphedema (e.g. due to mastectomy)

12. Other deviation of laboratory parameter(s) at V1 that is:

- clinically significant or

- 2x ULN (upper limit of normal), unless the deviation is justified by a previously known not clinically relevant condition, e.g. Gilbert's syndrome)

13. Dietary habits that may interfere with the study objectives:

- Eating disorder

- Subjects with dietary restriction that may affect the study outcome

- Participation in a weight loss program

14. Use of following medication/supplementation within the last 4 weeks prior to V1 and during the study, according to investigator's jugdement:

- Drugs or supplements that can influence SBP or DBP (e.g. ACE inhibitors, diuretics, calcium channel or ß-blockers, grape seed extract, coenzyme Q10 etc.)

- Lipid lowering drugs (affecting lipid metabolism, platelet function or antioxidant status, etc.) or dietary or health supplements (e.g. omega-3 fatty acids, green tea extract, calcium, red yeast rice, phytosterols (incl. enriched products such as e.g. Becel), oat fiber, niacin, soy protein, psyllium seed husk, glucomannan, chitosan or probiotics/prebiotics)

- Drugs that can significantly influence cholesterol levels (e.g. corticosteroids, amiodarone, anabolic steroids)

- Medications (e.g. statins, renin angiotensin system inhibitors, nebivolol, carvedilol, calcium channel blockers) or supplements (e.g. cocoa) that can influence vascular endothelial function and/or blood flow within the last 4 weeks prior to V1 and during the study

- Antiplatelet agents and / or anticoagulants (e.g. warfarin, acetylsalicylic acid)

15. Use of weight loss treatment

16. Drug abuse

17. Alcohol abuse (men: =21 units/week, women: =14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

18. Reported participation in night shift work 2 weeks prior to V1 and/or during the study

19. Women of child-bearing potential: pregnant or breast-feeding

20. Participation in another study or blood donation during the last 30 days prior to V1

21. Any other reason deemed suitable for exclusion as per investigator's judgment

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
WAK2017
WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
Placebo
One (1) ml IP should be taken with breakfast and one (1) ml with supper every day

Locations

Country Name City State
Germany analyze & realize GmbH Berlin
Germany BioTeSys GmbH Esslingen Baden Würtemberg

Sponsors (1)

Lead Sponsor Collaborator
Analyze & Realize

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Endo-PAT RHI value Change of EndoPAT score RHI measurement Visit 2 to Visit 4. EndoPAT parameter (Reactive Hyperemia Index (RHI) will be assessed per Endo-PAT 2000 according to standardized procedures provided by the manufacturer (Itamar Medical Ltd., Israel), at Visit 2 and Visit 4 Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2
Secondary EndoPAT Augmentation Index (AI) Change of EndoPAT parameter Augmentation Index (AI) will be assessed per Endo-PAT 2000 according to standardized procedures provided by the manufacturer (Itamar Medical Ltd., Israel), at Visit 2 and Visit 4 Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2
Secondary Systolic Blood Pressure Change in Systolic Blood Pressure after 6 weeks ± 3 Visit 2 versus Visit 3 42 days ± 3
Secondary Diastolic Blood Pressure Change in Diastolic Blood Pressure after 6 weeks ± 3 Visit 2 versus Visit 3 42 days ± 3
Secondary Systolic Blood Pressure Change in Systolic Blood Pressure after 12 weeks ± 6 Visit 2 versus Visit 4 84 weeks ± 6
Secondary Diastolic Blood Pressure Change in Diastolic Blood Pressure after 12 weeks ± 6 Visit 2 versus Visit 4 84 days ± 6
Secondary Low Density Lipoprotein cholestorol (LDL-C) Change in LDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum LDL-C concentrations. 42 days ± 3
Secondary Low Density Lipoprotein cholestorol (LDL-C) Change in LDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum LDL-C concentrations. 84 days ± 6
Secondary non-High Density Lipoprotein cholestorol (non-HDL-C) Change in non-HDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum non-HDL-C concentrations. The non-HDL cholesterol values are obtained by subtracting the HDL cholesterol value from the total cholesterol. 42 days ± 3
Secondary non-High Density Lipoprotein cholestorol (non-HDL-C) Change in non-HDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum non-HDL-C concentrations. The non-HDL cholesterol values are obtained by subtracting the HDL cholesterol value from the total cholesterol 84 days ± 6
Secondary Total Cholestorol (TC) Change in TC concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum Total Cholestorol (TC) concentrations. 42 days ± 3
Secondary Total Cholestorol (TC) Change in TC concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum Total Cholestorol (TC) concentrations. 84 days ± 6
Secondary High Density Lipoprotein cholestorol (HDL-C) Change in HDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum HDL-C concentrations. 42 days ± 3
Secondary High Density Lipoprotein cholestorol (HDL-C) Change in HDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum HDL-C concentrations. 84 days ± 6
Secondary Triglycerides (TG) Change in TG concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum TG concentrations. 42 days ± 3
Secondary Triglycerides (TG) Change in TG concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum TG concentrations. 84 days ± 6
Secondary LDL-C/HDL-C ratio Change in LDL-C/HDL-C ratio after 6 weeks ± 3 Visit 2 versus Visit 3. 42 days ± 3
Secondary LDL-C/HDL-C ratio Change in LDL-C/HDL-C ratio after 12 weeks ± 6 Visit 2 versus Visit 4. 84 days ± 6
Secondary TC/HDL-C ratio Change in TC/HDL-C ratio after 6 weeks ± 3 Visit 2 versus Visit 3. 42 days ± 3
Secondary TC/HDL-C ratio Change in TC/HDL-C ratio after 12 weeks ± 6 Visit 2 versus Visit 4. 84 days ± 6
Secondary SCORE Value The SCORE value will be assessed on V2 - V4 using the European Low Risk Chart by the European Society of Cardiology (Perk et al., 2012), during biometric assess-ment. 42 days ± 3
Secondary SCORE Value The SCORE value will be assessed on V2 - V4 using the European Low Risk Chart by the European Society of Cardiology (Perk et al., 2012), during biometric assess-ment. 84 days ± 6
Secondary Global Evaluation of benefit Both the subjects and investigator(s) will evaluate independently the benefit of the IP by means of a global scaled evaluation with "very good", "good", "moderate" and "poor". 84 days ± 6
See also
  Status Clinical Trial Phase
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT05997303 - Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT03918486 - Caretaker vs. Routine Blood Pressure Sphygmomanometer
Completed NCT03410342 - The Effects of Types of Fruits and Vegetables on Vascular Function N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT04087070 - Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
Completed NCT03294928 - Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers N/A
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03997461 - Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device N/A
Completed NCT03290716 - Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China N/A
Recruiting NCT06460233 - Blood Pressure Changes After Bariatric Surgery
Recruiting NCT05196048 - Blood Pressure Sensor of Watch-type Device With ECG Technology
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Completed NCT02924454 - Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol. Phase 4
Completed NCT02451059 - Reducing Socioeconomic Disparities in Health at Pediatric Visits N/A
Active, not recruiting NCT02670967 - Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials N/A
Completed NCT02271633 - Nitrate Supplementation; Source Phase 4
Completed NCT02239744 - Intervention Study on the Health Impact of Air Filters in Chinese Adults N/A